Adaptimmune Therapeutics PLC (ADAP) Stock Rating Upgraded by Zacks Investment Research
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Monday.
According to Zacks, “Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom. “
Separately, Raymond James Financial Inc. initiated coverage on shares of Adaptimmune Therapeutics PLC in a report on Friday, September 30th. They issued an “outperform” rating and a $16.00 price target on the stock. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $15.95.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) traded up 3.91% during midday trading on Monday, reaching $6.65. 169,014 shares of the company’s stock were exchanged. Adaptimmune Therapeutics PLC has a 12 month low of $6.19 and a 12 month high of $14.78. The firm has a 50 day moving average of $7.06 and a 200-day moving average of $8.43. The stock’s market cap is $470.72 million.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last released its quarterly earnings data on Monday, August 8th. The company reported ($0.05) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.16. Adaptimmune Therapeutics PLC had a negative net margin of 427.33% and a negative return on equity of 21.36%. On average, equities research analysts predict that Adaptimmune Therapeutics PLC will post ($1.09) earnings per share for the current year.
Large investors have recently made changes to their positions in the stock. Adage Capital Partners GP L.L.C. increased its stake in shares of Adaptimmune Therapeutics PLC by 34.8% in the second quarter. Adage Capital Partners GP L.L.C. now owns 1,550,000 shares of the company’s stock worth $12,633,000 after buying an additional 400,000 shares in the last quarter. Rathbone Brothers plc increased its stake in shares of Adaptimmune Therapeutics PLC by 124.7% in the second quarter. Rathbone Brothers plc now owns 450,525 shares of the company’s stock worth $3,672,000 after buying an additional 250,000 shares in the last quarter. Opaleye Management Inc. bought a new stake in shares of Adaptimmune Therapeutics PLC during the first quarter worth $1,425,000. New Leaf Venture Partners L.L.C. bought a new stake in shares of Adaptimmune Therapeutics PLC during the second quarter worth $1,035,000. Finally, Renaissance Technologies LLC increased its stake in shares of Adaptimmune Therapeutics PLC by 286.3% in the first quarter. Renaissance Technologies LLC now owns 113,200 shares of the company’s stock worth $920,000 after buying an additional 83,900 shares in the last quarter. 45.11% of the stock is currently owned by institutional investors and hedge funds.
Adaptimmune Therapeutics PLC Company Profile
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.
Receive News & Stock Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related stocks with our FREE daily email newsletter.